Cargando…

Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancer

BACKGROUND: Ranpirnase (Rap) is an amphibian ribonuclease with reported antitumor activity, minimal toxicity, and negligible immunogenicity in clinical studies, but the unfavorable pharmacokinetics and suboptimal efficacy hampered its further clinical development. To improve the potential of Rap-bas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Donglin, Cardillo, Thomas M, Wang, Yang, Rossi, Edmund A, Goldenberg, David M, Chang, Chien-Hsing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015355/ https://www.ncbi.nlm.nih.gov/pubmed/24606732 http://dx.doi.org/10.1186/1476-4598-13-53

Ejemplares similares

Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer
por: Cardillo, Thomas M., et al.
Publicado: (2020)

Interferon-λ1 Linked to a Stabilized Dimer of Fab Potently Enhances both Antitumor and Antiviral Activities in Targeted Cells
por: Liu, Donglin, et al.
Publicado: (2013)

Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma
por: Porta, Camillo, et al.
Publicado: (2008)

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
por: Goldenberg, David M., et al.
Publicado: (2015)

Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
por: Goldenberg, David M., et al.
Publicado: (2020)

Potent anti-tumor activity of CD45RA-targeting Hm3A4-Ranpirnase against myeloid lineage leukemias
por: Li, Sisi, et al.
Publicado: (2022)

TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer
por: Xu, Caili, et al.
Publicado: (2023)

Potent antitumor activity of cepharanthine against triple-negative breast cancer spheroids compared with tetrandrine
por: Kiyomi, Anna, et al.
Publicado: (2020)

Antiviral Ranpirnase TMR-001 Inhibits Rabies Virus Release and Cell-to-Cell Infection In Vitro
por: Smith, Todd G., et al.
Publicado: (2020)

Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer
por: Jeon, Yeonjin, et al.
Publicado: (2022)

Correlation of TROP-2 expression with clinical–pathological characteristics and outcome in triple-negative breast cancer
por: Izci, Hava, et al.
Publicado: (2022)

Trop-2 Therapy in Metastatic Triple-Negative Breast Cancer in Italy: Clinical Opportunity and Regulatory Pitfalls
por: Bravaccini, Sara, et al.
Publicado: (2021)

Heterologous prime-boost cellular vaccination induces potent antitumor immunity against triple negative breast cancer
por: Niavarani, Seyedeh-Raheleh, et al.
Publicado: (2023)

Enhancing the antitumor potency of T cells redirected by bispecific antibodies
por: Chang, Chien-Hsing, et al.
Publicado: (2017)

Ranpirnase (OKG-0301), a Novel Ribonuclease, Demonstrates Antiviral Activity against Adenovirus in the Ad5/NZW Rabbit Ocular Replication Model
por: Romanowski, Eric G., et al.
Publicado: (2022)

Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells
por: Okajima, Daisuke, et al.
Publicado: (2021)

Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer
por: Liu, Huicheng, et al.
Publicado: (2021)

Clinicopathologic significance of TROP2 and phospho-TROP2 in gastric cancer
por: Kushiyama, Shuhei, et al.
Publicado: (2021)

The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
por: Goldenberg, David M., et al.
Publicado: (2018)

LPM3770277, a Potent Novel CDK4/6 Degrader, Exerts Antitumor Effect Against Triple-Negative Breast Cancer
por: Qiu, Jiahao, et al.
Publicado: (2022)

Thioridazine has potent antitumor effects on lung cancer stem-like cells
por: Shen, Jiani, et al.
Publicado: (2017)

Trop petits pour Dieu /
por: Laederach, Monique, 1938-
Publicado: (1986)

Une trop bruyante solitude/
por: Hrabal, Bohumil, 1914-1997
Publicado: (1983)

Une fin trop précoce?
por: Rayson, Daniel
Publicado: (2022)

Anti-CD22/CD20 Bispecific Antibody with Enhanced Trogocytosis for Treatment of Lupus
por: Rossi, Edmund A., et al.
Publicado: (2014)

Monoclonal antibodies targeting CD20
por: Chang, Chien-Hsing, et al.
Publicado: (2013)

The nature of triple-negative breast cancer classification and antitumoral strategies
por: Kim, Songmi, et al.
Publicado: (2020)

A Single Domain–Based Anti-Her2 Antibody Has Potent Antitumor Activities
por: Wu, Xiaoqiong, et al.
Publicado: (2018)

A Novel Monoclonal Antibody Targeting Cancer-Specific Plectin Has Potent Antitumor Activity in Ovarian Cancer
por: Perez, Samantha M., et al.
Publicado: (2021)

A Novel Class of Anti-HIV Agents with Multiple Copies of Enfuvirtide Enhances Inhibition of Viral Replication and Cellular Transmission In Vitro
por: Chang, Chien-Hsing, et al.
Publicado: (2012)

Antitumor Activity of Noscapine in Combination with Doxorubicin in Triple Negative Breast Cancer
por: Chougule, Mahavir B., et al.
Publicado: (2011)

An anti-TROP2 monoclonal antibody TrMab-6 exerts antitumor activity in breast cancer mouse xenograft models
por: Tanaka, Tomohiro, et al.
Publicado: (2021)

Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: A promising biomarker and therapeutic target for pancreatic cancer
por: Liu, Donglin, et al.
Publicado: (2015)

Trop-2 in Upper Tract Urothelial Carcinoma
por: Tomiyama, Eisuke, et al.
Publicado: (2022)

Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody
por: Raji, Rhoda, et al.
Publicado: (2011)

Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan
por: Zhao, Ming, et al.
Publicado: (2023)

Antitumor activity of new chemical compounds in triple negative mammary adenocarcinoma models
por: Giolito, María V, et al.
Publicado: (2020)

Identification and Characterization of Specific Nanobodies against Trop-2 for Tumor Targeting
por: Hu, Yaozhong, et al.
Publicado: (2022)

Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers
por: Vranic, Semir, et al.
Publicado: (2022)

TAK228 enhances antitumor activity of eribulin in triple negative breast cancer
por: Owusu-Brackett, Nicci, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ac38ije6mfuue6nm5mu8gpq8q5